insights_auto
Why is DMN down ५.११%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
€ ०.०५९
arrow_downward
-५.११%(-०.००३२) 1D
नोभेम्बर २०, २२:००:०० GMT+१ · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.५१ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
Open
€ ०.०६
High
€ ०.०६
Low
€ ०.०६
Mkt. cap
१३.५१ करोड
Avg. vol.
०.००
Volume
०.००
52-wk high
€ १.८०
52-wk low
€ ०.०५
No. of employees
४२
News stories
From web sources and news partners
TradingView
·
२ घण्टा पहिले
Stock Market Crash: Nasdaq, S&P 500 Suffer Worst Weekly Losses in Years
Traders Union
·
८ घण्टा पहिले
VIX fear index hits highest level since April 2025 as S&P 500 plunges
Beinsure
·
५ घण्टा पहिले
S&P 500 forecast for 2027: Wall Street expects a rebound after an 11.6% drop fueled by AI fears
JournalArta
·
४७ मिनेट पहिले
S&P 500 Loses Nearly All Its 2026 Gains in Sudden Reversal
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB